MedTrace Logo

A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

NCT07129382 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-09-10

No results posted yet for this study

Summary

" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks.

Part 2 (Efficacy and Safety Assessment): A randomized, double-blind, placebo-controlled evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment.

The resulting data will provide preliminary evidence on the safety and efficacy profile of CS32582, informing its subsequent development strategy.

Conditions

Interventions

DRUG

CS32582 capsule（low dose） or matched placebo

CS32582 capsule（low dose） or matched placebo，4 weeks

DRUG

CS32582 capsule（high dose） or matched placebo

CS32582 capsule（high dose） or matched placebo，4 weeks

DRUG

CS32582 capsule（low dose）

CS32582 capsule（low dose），12 weeks

DRUG

CS32582 capsule（medium dose）

CS32582 capsule（medium dose），12 weeks

DRUG

CS32582 capsule（high dose）

CS32582 capsule（high dose），12 weeks

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-08
Primary Completion
2027-09-18
Completion
2027-09-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07129382 on ClinicalTrials.gov